Inhibitors of β-secretase

US8981112B2 · kind B2 · utility

Assignees

• Vitae Pharmaceuticals, LLC · US
• Boehringer Ingelheim International GmbH · DE

Inventors

• Yuri Bukhtiyarov · Boothwyn, US
• Salvacion Cacatian · Conshohocken, US
• Lawrence Wayne Dillard · Yardley, US
• Cornelia Dorner-Ciossek · Ingelheim am Rhein, DE
• Klaus Fuchs · Ingelheim am Rhein, DE
• Lanqi Jia · Horsham, US
• Deepak S. Lala · North Wales, US
• Angel Morales-Ramos · Blue Bell, US
• Jonathan Timothy Reeves · Ridgefield, US
• Suresh B. Singh · Kendall Park, US
• Shankar Venkatraman · Lansdale, US
• Zhenrong Xu · Forest Park, US
• Jing Yuan · Lansdale, US
• Yi Zhao · Blue Bell, US
• Yajun Zheng · Hockessin, US
• Georg Rast · Singen, DE

Key dates

• Filing date: Mar 4, 2013
• Grant date: Mar 17, 2015
• Expiry date: Mar 4, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D407/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates.